类风湿关节炎：抗TNF以外的生物疗法。
Rheumatoid arthritis: Biological therapy other than anti-TNF.
作者信息
Rossi Daniela, Modena Vittorio, Sciascia Savino, Roccatello Dario
机构信息
Center of Research of Immunopathology and Rare Diseases (CMID), Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Giovanni Bosco Hospital, Turin, Italy.
Center of Research of Immunopathology and Rare Diseases (CMID), Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Giovanni Bosco Hospital, Turin, Italy.
出版信息
Int Immunopharmacol. 2015 Aug;27(2):185-8. doi: 10.1016/j.intimp.2015.03.019. Epub 2015 Mar 31.
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and is characterized by synovitis that causes joint damage. The introduction of biologic agents has made it possible to induce remission in many patients and inhibit joint damage. Activated T cells in RA patients proliferate and stimulate the production of pro-inflammatory cytokines including tumor necrosis factor (TNF) and interleukin 6 that play important roles in RA pathogenesis. The most widely used biologic agents indicated for RA inhibit the activity of TNF. However, newly developed biologic drugs targeting different pathways are now currently part of the therapeutic options to induce remission in patients with RA. The present review focuses on biologic agents directed at molecular targets different from TNF and addresses the possible advantages of these drugs.
类风湿性关节炎（RA）是最常见的自身免疫性疾病之一，其特征是滑膜炎导致关节损伤。生物制剂的引入使许多患者能够实现病情缓解并抑制关节损伤。RA患者体内活化的T细胞增殖并刺激促炎细胞因子的产生，包括在RA发病机制中起重要作用的肿瘤坏死因子（TNF）和白细胞介素6。用于RA的最广泛使用的生物制剂可抑制TNF的活性。然而，目前针对不同途径开发的新型生物药物已成为诱导RA患者病情缓解的治疗选择的一部分。本综述重点关注针对不同于TNF的分子靶点的生物制剂，并探讨这些药物可能具有的优势。
Zotero 插件